Entrar/Registro  
HOME SPANISH
 
Cirujano General
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Cirujano General >Year 2008, Issue S1


Capdeville GD
Gatrointestinal stromal tumors. Medical treatment
Cir Gen 2008; 30 (S1)

Language: Español
References: 15
Page: 23-26
PDF: 4. Kb.


Full text




ABSTRACT

Gastrointestinal stromal tumours (GIST) are uncommon: they represent 0.2% of the gastrointestinal neoplasms, and they have a subestimated prevalence. Considering the GIST’s potential malignancy, the clinician must consider histopathology, anatomopathology, and immunohistochemistry in order to determine if they are kit-receptor positive, and if the patients are candidates to receive imatinib treatment.
Imatinib mesylate is a well-tolerated treatment, administered orally. It has a mild and moderated toxicity; it is effective for these types of tumours, particularly in patients with irresecable disease and/or non-resectable metastasis. It is advisable to non-resectable and metastasic tumours with daily doses of 400 to 800 mg.
So far, several studies are being carried out to define more accurately the specifications and administration of neoadjuvant and adjuvant treatments.


Key words: GIST, gastrointestinal neoplasms, C-Kit receptor (CD117), adjuvant therapy, coadjuvant therapy, imatinib mesylate.


REFERENCIAS

  1. Altamirano LJ, Capdeville GD, Castruita AAL, Cortés EP, Erazo VA, Gaona NR, et al. Tratamiento médico. Gac Mex Oncol 2005; 4 (Suppl 1): 28-30.

  2. Miettinen M, Sobin LH. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a references to CD117 (KIT). Mod Pathol 2000; 13: 1143-1142.

  3. Pidhorecky J, Cheney RT, Kraybill W, Gibbs JF. Gastrointestinal stromal tumors. Current diagnosis, biologic behavior and management. Annals of Surgical Oncol 2000; 7: 705-712.

  4. El-Rifai W, Sarlomo-Rikala M, Anderson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Res 2000; 60: 3899-3903.

  5. Miettinen M, Sobin LH. Gastrointestinal stromal/smooth muscle tumors (GISTs). Primary in the omento and mesentery. Clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109-1118.

  6. Fletcher DM, Berman J, Corless CH, Gorstein F, Lasota J. Lonley J, Miettinen M, et al. Diagnosis of gastrointestinal stromal tumors. A consensus approach. Hum Pathol 2002; 33: 4-59-465.

  7. De Saint ASN, Fletcher CDM. Gastrointestinal stromal tumors. An update. Sarcoma 1998; 2: 133-41.

  8. Yantiss RK, Spiro IJ, Compton CC, et al. Gastrointestinal stromal tumors versus intra-abdominal fibromatosis of the bowel wall. A Clinically important differential diagnosis. Am J Surg Pathol 2000; 24: 947-57.

  9. Miettinen M. Are desmoid tumors KIT positive? Am Surg Pathol 2001; 25: 549-50.

  10. Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92: 657-662.

  11. Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32: 578-582.

  12. Lasota J, Wosniak A, Sarlomo-Rikala M, Ryz J, Morder R, Nassar A, Sobón LH, Miettinen M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A Study of 200 cases. Am J Pathol 2000; 156: 791-795.

  13. Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the Gut. Mod Pathol 2003; 16: 366-375.

  14. Casali PG, et al. Proc Am Soc Clin Oncol 2002; 21: 413ª, Abstract 1650.

  15. Verweij, et al. Abstract 3272, Proc Am Soc Clin Oncol 2003; 22: 814.






>Journals >Cirujano General >Year 2008, Issue S1
 

· Journal Index 
· Links 






       
Copyright 2019